Galactosidase Alpha (GLA) Antibody

Product Graph
195€ (20 µl)

Por favor contáctenos para obtener información detallada sobre el precio y disponibilidad.

935106861
info@markelab.com
name
Galactosidase Alpha (GLA) Antibody
category
Primary Antibodies
provider
Abbexa
reference
abx001425
tested applications
ELISA, WB, IF/ICC

Description

GLA Antibody is a Rabbit Polyclonal antibody against GLA. This gene encodes a homodimeric glycoprotein that hydrolyses the terminal alpha-galactosyl moieties from glycolipids and glycoproteins. This enzyme predominantly hydrolyzes ceramide trihexoside, and it can catalyze the hydrolysis of melibiose into galactose and glucose. A variety of mutations in this gene affect the synthesis, processing, and stability of this enzyme, which causes Fabry disease, a rare lysosomal storage disorder that results from a failure to catabolize alpha-D-galactosyl glycolipid moieties.

Documents del producto

Instrucciones
Data sheet
Descargar

Product specifications

Category
Primary Antibodies
Immunogen Target
Galactosidase Alpha (GLA)
Host
Rabbit
Reactivity
Human, Mouse
Recommended Dilution
ELISA: 1 µg/ml, WB: 1/500 - 1/2000, IF/ICC: 1/50 - 1/100. Optimal dilutions/concentrations should be determined by the end user.
Clonality
Polyclonal
Conjugation
Unconjugated
Isotype
IgG
Purification
Purified by affinity chromatography.
Size 1
20 µl
Size 2
100 µl
Size 3
2 × 100 µl
Form
Liquid
Tested Applications
ELISA, WB, IF/ICC
Buffer
PBS, pH 7.3, containing 0.02% sodium azide, 50% glycerol.
Availability
Shipped within 5-10 working days.
Storage
Aliquot and store at -20°C. Avoid repeated freeze/thaw cycles.
Dry Ice
No
UniProt ID
P06280
Gene ID
2717
NCBI Accession
NP_000160.1
Background
Antibody anti-GLA
Status
RUO
Note
Concentration: > 0.2 mg/ml -

Descripción

Related Products

EH0745

Human GLA (Alpha-galactosidase A) ELISA Kit

Ver Producto
EP2627

Porcine GLA (Alpha-galactosidase A) ELISA Kit

Ver Producto
FNab00328

GLA antibody

GLA, also named as Melibiase, Agalsidas and Alpha-galactosidase A, Belongs to the glycosyl hydrolase 27 family. It hydrolysis of terminal, non-reducing alpha-D-galactose residues in alpha-D-galactosides, including galactose oligosaccharides, galactomannans and galactolipids. Fabry disease is an X-linked lysosomal storage disorder resulting from the deficient activity of GLA. Enzyme replacement therapy(ERT) with GLA is currently the most effective therapeutic strategy for patients with Fabry disease, a lysosomal storage disease.

Ver Producto